<p>Biocon Ltd, a global biopharmaceuticals company, announced on Friday that the board of its subsidiary Biocon Biologics India Limited has approved a primary equity investment by Tata Capital Growth Fund.</p>.<p>As per the terms of the proposed agreement, Tata Capital will invest Rs 225 crore for a 0.85 percent minority stake in the biosimilar business, valuing Biocon Biologics at an equity valuation of Rs 26,250 crore and an enterprise valuation of Rs 30,400 crore, Biocon said in a statement.</p>.<p>The transaction is subject to standard condition precedents and approvals.</p>.<p>Post the completion of this transaction, Biocon will hold 95.25 percent stake in Biocon Biologics, the company added.</p>.<p>Dr Christiane Hamacher, CEO, Biocon Biologics, said, "This equity infusion is the next step in our journey of unlocking value. Through prudent investments in R&D and high- quality manufacturing infrastructure we are confident of achieving our aspiration of serving 5 million patients through our biosimilars portfolio and achieving a target revenue of USD one billion in FY22."</p>.<p>Akhil Awasthi, Managing Partner, Tata Growth PE, said, "The investment brings together 150 plus years of brand equity of Tatas and a very strong R&D based entrepreneur in Dr Kiran Mazumdar-Shaw."</p>
<p>Biocon Ltd, a global biopharmaceuticals company, announced on Friday that the board of its subsidiary Biocon Biologics India Limited has approved a primary equity investment by Tata Capital Growth Fund.</p>.<p>As per the terms of the proposed agreement, Tata Capital will invest Rs 225 crore for a 0.85 percent minority stake in the biosimilar business, valuing Biocon Biologics at an equity valuation of Rs 26,250 crore and an enterprise valuation of Rs 30,400 crore, Biocon said in a statement.</p>.<p>The transaction is subject to standard condition precedents and approvals.</p>.<p>Post the completion of this transaction, Biocon will hold 95.25 percent stake in Biocon Biologics, the company added.</p>.<p>Dr Christiane Hamacher, CEO, Biocon Biologics, said, "This equity infusion is the next step in our journey of unlocking value. Through prudent investments in R&D and high- quality manufacturing infrastructure we are confident of achieving our aspiration of serving 5 million patients through our biosimilars portfolio and achieving a target revenue of USD one billion in FY22."</p>.<p>Akhil Awasthi, Managing Partner, Tata Growth PE, said, "The investment brings together 150 plus years of brand equity of Tatas and a very strong R&D based entrepreneur in Dr Kiran Mazumdar-Shaw."</p>